# RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care

> **NCT07187570** · PHASE3 · RECRUITING · sponsor: **Region Stockholm** · enrollment: 1600 (estimated)

## Conditions studied

- Atrial Fibrillation (AF)

## Interventions

- **DRUG:** Dapagliflozin 10 mg once daily

## Key facts

- **NCT ID:** NCT07187570
- **Lead sponsor:** Region Stockholm
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-03
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 1600 (ESTIMATED)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07187570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07187570, "RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07187570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*